Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  29 (2025)
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 28 , ISSUE 11 ( November, 2024 ) > List of Articles

Original Article

The Clinical Impression of NDM-producing Acinetobacter baumannii in Intensive Care Units of the University Referral Hospital in North India

Sangeeta Singh, Anuragani Verma, Vimala Venkatesh, Sheetal Verma, D Himanshu Reddy, Avinash Agrawal

Keywords : Antimicrobial resistance, Bloodstream infection, Carbapenem-resistant Acinetobacter baumannii, Intensive care unit, New Delhi metallo-β-lactamases

Citation Information : Singh S, Verma A, Venkatesh V, Verma S, Reddy DH, Agrawal A. The Clinical Impression of NDM-producing Acinetobacter baumannii in Intensive Care Units of the University Referral Hospital in North India. Indian J Crit Care Med 2024; 28 (11):1044-1049.

DOI: 10.5005/jp-journals-10071-24834

License: CC BY-NC 4.0

Published Online: 30-10-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aims and background: Carbapenem-resistant Acinetobacter baumannii (CRAb), a major public health threat, causes severe infections in Intensive Care Unit (ICU) patients. It resists β-lactam antibiotics through mechanisms like New Delhi metallo-beta-lactamase (NDM). Materials and methods: In ICU patients, 69 Acinetobacter species were isolated from 86 non-fermenting Gram-negative bacilli. Isolates were identified using biochemical methods and Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MS), and carbapenem resistance detection was done by both phenotypic (mCIM and eCIM) and molecular methods. Results: Out of 66 A. baumannii, 61 were carbapenem-resistant, with 20 confirmed as NDM producers. NDM-positive isolates exhibited higher resistance and were associated with significant mortality (75%). Conclusion: NDM-positive Acinetobacter isolates are significant ICU pathogens with poor outcomes. Key risk factors include prolonged ICU stays, prior antimicrobial use, and inadequate therapy. Early detection and infection control are crucial. Clinical significance: NDM-positive Acinetobacter infections in ICU patients are linked to poor outcomes, highlighting the need for early detection and control measures.

HTML PDF Share
  1. Jesudason T. WHO publishes updated list of bacterial priority pathogens. Lancet Microbe 202427:100940. DOI: 10.1016/j.lanmic.2024.07.003.
  2. Rajni E, Kataria S, Garg V, Jorwal A, Bacchani D, Sharma R. Carbapenem resistant Acinetobacter baumannii: Current status of problem in a tertiary care hospital, Jaipur. Med J Dr. DY Patil Univ 2024;17(2):304–310. DOI: 10.4103/mjdrdypu.mjdrdypu_646_22.
  3. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021;10(3):373. DOI: 10.3390/pathogens10030373.
  4. Grewal AS, Thapa K, Sharma N, Singh S. New Delhi metallo-β-lactamase-1 inhibitors for combating antibiotic drug resistance: Recent developments. Med Chem Res 2020;29(8):1301–1320. DOI: 10.1007/s00044-020-02580.
  5. Aruhomukama D, Najjuka CF, Kajumbula H, Okee M, Mboowa G, Sserwadda I, et al. Bla VIM-and bla OXA-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda. BMC Infect Dis 2019;19:1–8 DOI: 10.1186/s12879-019-4510-5.
  6. Lyu C, Zhang Y, Liu X, Wu J, Zhang J. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. BMC Infect Dis 2020;20:1–4. DOI: 10.1186/s12879-020-05026-2.
  7. Adler A, Ghosh H, Gross A, Rechavi A, Lasnoy M, Assous MV, et al. Clinical and molecular features of NDM-producing Acinetobacter baumannii in a multicenter study in Israel. Ann Clin Microbiol Antimicrob 2023;22(1):52. DOI: 10.1186/s12941-023-00607-w.
  8. Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics 2020;9(3):119. DOI: 10.3390/antibiotics9030119.
  9. Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. J Clin Microbiol 2021;59(12):10–128. DOI: 10.1128/jcm.00213-21.
  10. Weinstein MP, Lewis JS. The Clinical and Laboratory Standards Institute Subcommittee on antimicrobial susceptibility testing: Background, organization, functions, and processes. J Clin Microbiol 2020;58(3):e01864–19. DOI: 10.1128/JCM.01864-19.
  11. Cavallo I, Oliva A, Pages R, Sivori F, Truglio M, Fabrizio G, et al. Acinetobacter baumannii in the critically ill: Complex infections get complicated. Front Microbiol 2023;14:1196774. DOI: 10.3389/fmicb.2023.1196774.
  12. Piri Gharaghie T, Doosti A, Mirzaei SA. Prevalence and antibiotic resistance pattern of Acinetobacter spp. infections in Shahrekord medical centers. Development Biol 2021;13(4):35–46. DOI: 10.30495/jdb.2021.686587.
  13. Papadopoulou M, Deliolanis I, Polemis M, Vatopoulos A, Psichogiou M, Giakkoupi P. Characteristics of the genetic spread of carbapenem-resistant Acinetobacter baumannii in a Tertiary Greek Hospital Genes 2024;15(4):458. DOI: 10.3390/genes15040458.
  14. Prayag PS, Patwardhan SA, Joshi RS, Panchakshari SP, Rane T, Prayag AP, et al. Enzyme patterns and factors associated with mortality among patients with carbapenem resistant Acinetobacter baumannii (CRAB) Bacteremia: Real world evidence from a Tertiary Center in India. Indian J Crit Care Med 2023;27(9):663. DOI: 10.5005/jp-journals-10071-24534.
  15. Pragasam AK, Vijayakumar S, Bakthavatchalam YD, Kapil A, Das BK, Ray P, et. al. Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India. Indian J Med Microbiol 2016;34(4):433–441. DOI: 10.4103/0255-0857.195376.
  16. Rout BP, Dash SK, Otta S, Behera B, Praharaj I, Sahu KK. Colistin resistance in carbapenem non-susceptible Acinetobacter baumanii in a tertiary care hospital in India: Clinical characteristics, antibiotic susceptibility and molecular characterization. Mol Biol Rep 2024;51(1):357. DOI: 10.1007/s11033-023-08982-5.
  17. Rout BP, Dash SK, Otta S, Behera B, Praharaj I, Sahu KK. Molecular epidemiology of carbapenem and colistin resistant Acinetobacter baumanii. DOI: 10.21203/rs.3.rs-3339579/v1.
  18. Yohei Doi, Treatment options for Carbapenem-resistant Gram-negative bacterial infections. Clinical Infect Dis 2019;69(Supplement_7):S565–S575. DOI: 10.1093/cid/ciz830.
  19. Bose P, Rangnekar A, Desikan P. NDM-beta-lactamase-1: Where do we stand?. Indian J Med Res 2022;155(2):243–252. DOI: 10.4103/ijmr.IJMR_685_19.
  20. Serapide F, Guastalegname M, Gullì SP, Lionello R, Bruni A, Garofalo E, et al. Antibiotic treatment of Carbapenem-resistant Acinetobacter baumannii infections in view of the newly developed β-Lactams: A narrative review of the existing evidence. Antibiotics (Basel) 2024;13(6):506. DOI: 10.3390/antibiotics13060506.
  21. Bonnin RA, Poirel L, Nordmann P. New Delhi metallo-β-lactamase-producing Acinetobacter baumannii: A novel paradigm for spreading antibiotic resistance genes. Future Microbiol 2014;9(1):33–41. DOI: 10.2217/fmb.13.69.
  22. Wang J, Ning Y, Li S, Wang Y, Liang J, Jin C, et al. Multidrugresistant Acinetobacter baumannii strains with NDM1: Molecular characterization and in vitro efficacy of meropenembased combinations. Exp TherMed 2019;18(4):2924–2932. DOI: 10.3892/etm.2019.7927.
  23. Acman M, Wang R, van Dorp L, Shaw LP, Wang Q, Luhmann N, et al. Role of mobile genetic elements in the global dissemination of the carbapenem resistance gene bla NDM. Nat Commun 2022;13(1):1131. DOI: 10.1038/s41467-022-28819-2.
  24. Mitteregger D, Wessely J, Barišić I, Bedenić B, Kosak D, Kundi M. A variant carbapenem inactivation method (CIM) for Acinetobacter baumannii group with shortened time-to-result: rCIM-A. Pathogens 2022;11(4):482. DOI: 10.3390/pathogens11040482.
  25. Singh V, Agarwal J, Nath SS, Sharma A. Evaluation of direct antimicrobial susceptibility testing from positive flagged blood cultures in sepsis patients. Indian J Crit Care Med 2024;28(4):387–392. DOI: 10.5005/jp-journals-10071-24687.
  26. Blackwell GA, Hamidian M, Hall RM. IncM plasmid R1215 is the source of chromosomally located regions containing multiple antibiotic resistance genes in the globally disseminated Acinetobacter baumannii GC1 and GC2 clones. MSphere 2016;1(3):10–128. DOI: 10.1128/msphere.00117-16.
  27. Vila J, Martí S, Sanchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59(6):1210–1215. DOI: 10.1093/jac/dkl509.
  28. Bardhan T, Chakraborty M, Bhattacharjee B. Prevalence of colistin-resistant, carbapenem-hydrolyzing proteobacteria in hospital water bodies and out-falls of West Bengal, India. Int J Environ Res Public Health 2020;17(3):1007. DOI: 10.3390/ijerph17031007.
  29. Papazachariou A, Tziolos RN, Karakonstantis S, Ioannou P, Samonis G, Kofteridis DP. Treatment strategies of colistin resistance Acinetobacter baumannii infections. Antibiotics 2024;13(5):423. DOI: 10.3390/antibiotics13050423.
  30. Mathai AS, Oberoi A, Madhavan S, Kaur P. Acinetobacter infections in a tertiary level intensive care unit in northern India: Epidemiology, clinical profiles and outcomes. J Infect Public Health 2012;5(2):145–152. DOI: 10.1016/j.jiph.2011.12.002.
  31. Diep DT, Tuan HM, Ngoc KM, Vinh C, Dung TT, Phat VV, et al. The clinical features and genomic epidemiology of carbapenem-resistant Acinetobacter baumannii infections at a tertiary hospital in Vietnam. J Global Antimicrob Resist 2023;33:267–275. DOI: 10.1016/j.jgar.2023.04.007.
  32. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit. Frontiers in microbiology 2022;13:1045206. DOI: 10.3389/fmicb.2022.1045206.
  33. Nhu NT, Lan NP, Campbell JI, Parry CM, Thompson C, Tuyen HT, et al. Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. J Med Microbiol 2014;63(10):1386–1394. DOI: 10.1099/jmm.0.076646-0.
  34. Srikanth D, Joshi SV, Shaik MG, Pawar G, Bujji S, Kanchupalli V, Chopra S, Nanduri S. A comprehensive review on potential therapeutic inhibitors of nosocomial Acinetobacter baumannii superbugs. Bioorg Chem 2022;124:105849. DOI: 10.1016/j.bioorg.2022.105849.
  35. Abarca-Coloma L, Puga-Tejada M, Nuñez-Quezada T, Gómez-Cruz O, Mawyin-Muñoz C, Barungi S, et al. Risk factors associated with mortality in Acinetobacter baumannii infections: Results of a prospective cohort study in a Tertiary Public Hospital in Guayaquil, Ecuador. Antibiotics 2024;13(3):213. DOI: 10.3390/antibiotics13030213.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.